{"denoms":[{"counts":[{"groupId":"BG000","value":"534"},{"groupId":"BG001","value":"266"},{"groupId":"BG002","value":"800"}],"units":"Participants"}],"groups":[{"description":"Participants received TAS-102 orally with a starting dose of 35 mg/m\\^2/dose BID based on BSA along with BSC. The first dose of TAS-102 was administered in the morning of Day 1 of each cycle and the last dose was administered in the evening of Day 5, followed by rest on Day 6 and 7, treatment was repeated for next week starting from Day 8 to Day 12, followed by a 16-day rest starting from Day 13 to Day 28 (1 treatment cycle = 28 days). Participants received study medication until any of the discontinuation criteria were met.","id":"BG000","title":"TAS-102"},{"description":"Participants orally received TAS-102 matching placebo BID dose along with BSC with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5, followed by rest on Day 6 and 7, treatment was repeated for next week starting from Day 8 to Day 12, followed by a 16-day rest starting from Day 13 to Day 28 (1 treatment cycle). Participants received study medication until any of the discontinuation criteria.","id":"BG001","title":"Placebo"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"300"},{"groupId":"BG001","value":"148"},{"groupId":"BG002","value":"448"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"234"},{"groupId":"BG001","value":"118"},{"groupId":"BG002","value":"352"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.21","value":"61.5"},{"groupId":"BG001","spread":"10.51","value":"61.5"},{"groupId":"BG002","spread":"10.30","value":"61.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"208"},{"groupId":"BG001","value":"101"},{"groupId":"BG002","value":"309"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"326"},{"groupId":"BG001","value":"165"},{"groupId":"BG002","value":"491"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Analysis was performed in Intent-to-Treat (ITT) population which included all randomized participants."}